Medivir to present mature clinical data for fostrox + Lenvima at ESMO Conference and to host a webcast on September 16

Rhea-AI Summary

Medivir AB (NASDAQ Stockholm: MVIR) is set to present mature clinical data for its fostrox (fostroxacitabine) and Lenvima® (lenvatinib) combination therapy at the ESMO Congress in Barcelona on September 16, 2024. The presentation will focus on results from a phase 1b/2a study treating advanced hepatocellular carcinoma (HCC) that progressed after immunotherapy. Dr. Hong Jae Chon from CHA Bundang Medical Center in Korea will present the abstract.

Following the presentation, Medivir will host a webcast at 13:45 CET, featuring Dr. Chon and Dr. Pia Baumann, Medivir's CMO, to discuss the data and answer questions. Dr. Chon will also provide context by comparing the results to current second-line clinical practices for liver cancer treatment.

Positive

• Presentation of mature clinical data for fostrox + Lenvima combination therapy at ESMO Congress
• Phase 1b/2a study results for advanced HCC treatment to be revealed
• Webcast scheduled to discuss data and answer questions, indicating transparency
• Comparison with current second-line clinical practices to be provided, offering context for the results

Negative

• None.

STOCKHOLM, Sept. 12, 2024 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, has previously announced that detailed and mature data from the phase 1b/2a study of fostrox (fostroxacitabine) in combination with Lenvima® (lenvatinib) for the treatment of advanced hepatocellular carcinoma (HCC) will be presented at the European Society for Medical Oncology (ESMO) Congress in Barcelona, September 16, 2024.

The abstract, titled "Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed on immunotherapy combinations. Results from a multi-center phase 1b/2a study." will be presented by Dr Hong Jae Chon, CHA Bundang Medical Center in Korea.

After the presentation Medivir will also host a webcast where Dr Chon and Dr Pia Baumann, Chief Medical Officer at Medivir, will present the data and answer questions. The webcast will take place on September 16, at 13.45 CET, and will be streamed via a link on the website: www.medivir.com/investors/presentations.

In addition to the presentation of phase 1b/2a data, Dr Chon with his experience of treating liver cancer patients, will provide additional context to the data by comparing with what can be expected with current clinical practice in second-line.

The poster and the presentation from the webcast will be available on Medivir's website after the webcast.

For additional information, please contact:

Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com 

About fostrox

Fostrox is a liver-targeted inhibitor of DNA replication that delivers the cell-killing compound selectively to the tumor while minimizing the harmful effect on normal cells. This is achieved by coupling an active chemotherapy (troxacitabine) with a prodrug tail. This design enables fostrox to be administered orally and travel directly to the liver where the active substance is released locally in the liver. With this unique mechanism, fostrox has the potential to become the first liver-targeted, orally administered drug that can help patients with various types of liver cancer. A phase 1b monotherapy study with fostrox has been completed and a phase 1b/2a combination study in HCC is ongoing where it has shown encouraging anti-cancer efficacy with a good safety and tolerability profile.

About primary liver cancer

Primary liver cancer is the third leading cause of cancer-related deaths worldwide. Hepatocellular carcinoma (HCC) is the most common cancer that arises in the liver and it is the fastest growing cancer in the USA. Although existing therapies for advanced HCC can extend the lives of patients, treatment benefits are insufficient and death rates remain high. There are approximately 660,000 patients diagnosed with primary liver cancer per year globally and current five-year survival is less than 20 percent^1,2. HCC is a heterogeneous disease with diverse etiologies, and lacks defining mutations observed in many other cancers. This has contributed to the lack of success of molecularly targeted agents in HCC. The limited overall benefit, taken together with the poor overall prognosis for patients with intermediate and advanced HCC, results in a large unmet medical need.

About Medivir

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a drug candidate designed to selectively treat cancer cells in the liver and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

1) Rumgay et al.,European Journal of Cancer 2022 vol.161, 108-118.
2) Yang, J.D., Hainaut, P., Gores, G.J. et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16, 589-604 (2019).

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/medivir/r/medivir-to-present-mature-clinical-data-for-fostrox---lenvima-at-esmo-conference-and-to-host-a-webca,c4036638

The following files are available for download:

https://mb.cision.com/Main/652/4036638/2997636.pdf

Press release (PDF)

View original content:https://www.prnewswire.com/news-releases/medivir-to-present-mature-clinical-data-for-fostrox--lenvima-at-esmo-conference-and-to-host-a-webcast-on-september-16-302246468.html

SOURCE Medivir

FAQ

What will Medivir present at the ESMO Congress on September 16, 2024?

Medivir will present mature clinical data from a phase 1b/2a study of fostrox (fostroxacitabine) in combination with Lenvima® (lenvatinib) for the treatment of advanced hepatocellular carcinoma (HCC) that progressed on immunotherapy combinations.

Who will present Medivir's (MVIR) clinical data at the ESMO Congress?

Dr. Hong Jae Chon from CHA Bundang Medical Center in Korea will present the abstract and clinical data for Medivir at the ESMO Congress.

When and where will Medivir (MVIR) host a webcast to discuss the ESMO Congress presentation?

Medivir will host a webcast on September 16, 2024, at 13:45 CET. The webcast will be streamed via a link on the company's website: www.medivir.com/investors/presentations.

What additional context will be provided during Medivir's (MVIR) webcast on September 16, 2024?

Dr. Hong Jae Chon will provide additional context to the data by comparing it with what can be expected from current clinical practice in second-line treatment for liver cancer patients.